This is a news story, published by Investor's Business Daily, that relates primarily to Pfizer news.
For more Pfizer news, you can click here:
more Pfizer newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Alnylam stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Alnylam weakness today news, Pfizer stock news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Alnylam PharmaceuticalsInvestor's Business Daily
•
75% Informative
Alnylam Pharmaceuticals' drug, vutrisiran, tested its drug in patients with ATTR amyloidosis with cardiomyopathy.
After 30 months , patients were 13.8% less likely to die of any cause.
But investors were looking for a 32% risk reduction after 30 months .
Pfizer 's Vyndaqel , an approved treatment, brought in $3.32 billion in sales last year .
VR Score
75
Informative language
79
Neutral language
51
Article tone
formal
Language
English
Language complexity
46
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
4
Source diversity
2
Affiliate links
no affiliate links